Roivant Sciences Ltd - SIC # 8731 - COMMERCIAL PHY_SICAL AND BIOLOGICAL RESEARCH

Ticker Exchange SIC # Website Latest Ticker
ROIV Nasdaq 8731 http://roivant.com/

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for Roivant Sciences Ltd

Organon to Acquire Dermavant including its Innovative Dermatologic Therapy, VTAMA® (tapinarof) Cream, 1% - Sep 18th, 2024 11:30 am
Roivant Unveils New Pipeline Program Mosliciguat, A Potential First-In-Class and Best-In-Category Inhaled Once-Daily Soluble Guanylate Cyclase (sGC) Activator - Sep 10th, 2024 10:30 am
Pulmovant presents positive proof-of-concept data from the Phase 1b ATMOS study of Mosliciguat in Pulmonary Hypertension at European Respiratory Society Congress - Sep 10th, 2024 10:30 am
Roivant Provides Update on Graves’ Disease Development Program - Sep 9th, 2024 11:00 am
The Federal Reserve should refresh its mandate: Former presidential candidate Vivek Ramaswamy - Sep 4th, 2024 10:55 pm
Shareholders In Roivant Sciences (NASDAQ:ROIV) Should Look Beyond Earnings For The Full Story - Aug 22nd, 2024 11:03 am
Roivant Reports Financial Results for the First Quarter Ended June 30, 2024, and Provides Business Update - Aug 8th, 2024 11:00 am
Roivant to Report Financial Results for the First Quarter Ended June 30, 2024, and Provide Business Update on Thursday, August 8, 2024 - Jul 25th, 2024 8:05 pm
Roivant Reports Financial Results for the Fourth Quarter and Fiscal Year Ended March 31, 2024, and Provides Business Update - May 30th, 2024 11:00 am
Roivant to Report Financial Results for the Fourth Quarter and Fiscal Year Ended March 31, 2024, and Provide Business Update on Thursday, May 30, 2024 - May 16th, 2024 8:05 pm
Institutional investors are Roivant Sciences Ltd.'s (NASDAQ:ROIV) biggest bettors and were rewarded after last week's US$290m market cap gain - May 5th, 2024 12:45 pm
Roivant Announces Positive NEPTUNE Study Results for Brepocitinib in NIU, as well as Board Authorization for up to $1.5 Billion Share Repurchase Program, Including Repurchase of Entire Sumitomo Pharma Stake for $648 Million - Apr 2nd, 2024 11:00 am
Roivant Sciences Set to Join S&P MidCap 400; Sunrun to Join S&P SmallCap 600 - Mar 26th, 2024 10:22 pm
Roivant Sciences Third Quarter 2024 Earnings: Beats Expectations - Feb 14th, 2024 12:13 pm
Roivant Reports Financial Results for the Third Quarter Ended December 31, 2023, and Provides Business Update - Feb 13th, 2024 12:00 pm
Roivant Sciences Ltd President & COO Eric Venker Sells 96,950 Shares - Feb 10th, 2024 7:55 am
Roivant to Report Financial Results for the Third Quarter Ended December 31, 2023, and Provide Business Update on Tuesday, February 13, 2024 - Jan 30th, 2024 9:05 pm
Roivant Reports Positive Initial Phase 2 Results for Batoclimab in Graves’ Disease - Dec 20th, 2023 9:30 pm
Roche Completes Acquisition of Telavant from Roivant, Including Rights to Novel TL1A Directed Antibody (RVT-3101) for the Treatment of Inflammatory Bowel Disease - Dec 14th, 2023 2:00 pm
Roivant Announces Positive IMVT-1402 Initial 600 mg MAD Results that Confirm Best-in-Class Potential - Nov 28th, 2023 12:00 pm